Improving Diagnosis and Target Analysis (Target Structures) in Progressive or Recurrent Pediatric Tumors

The chances of recovery for children with cancer are high, but certain aggressive tumors, such as brain tumors or sarcomas, have high relapse rates after initial treatment and thus a poor prognosis. The standard treatment is usually a second course of chemotherapy or radiation therapy. It has since been demonstrated that many of these tumors have genetic alterations that could be targeted for treatment.

The earlier INFORM study (“Individualized Therapy for Relapsed Malignancies in Childhood”) showed that treatable genetic alterations (so-called “targetable alterations”) can be detected in approximately 50% of tumors and, were relevant to the further course of treatment for 41% of patients. For patients who do not meet the eligibility criteria for the INFORM study—either because their disease is not among the diagnoses included in the INFORM study, fresh tissue is not available, or no specific target structure can be detected in the tumor—the PTT2.0 study offers an alternative.

The PTT2.0 study was specifically developed to investigate genetic alterations in tumor cells in children with progressive or recurrent cancer. To this end, tumor tissue samples and a blood sample from each patient are analyzed using state-of-the-art methods, including DNA methylation analyses and gene panel sequencing. These methods help determine the exact genetic alterations and thus identify targeted treatment options using drugs specifically designed to address them. The goal of the PTT2.0 study is to investigate in which cases molecular analysis can confirm the diagnosis or determine it more precisely, how often treatable genetic alterations can be detected, and to what extent these findings influence subsequent treatment and improve its chances of success.

The study is non-interventional, which means that diagnostic procedures—not new treatments—are being tested. If genetic alterations are detected that could be treated with targeted therapy, this information will be shared with the treating physicians. They can then decide whether to incorporate these findings into the patient’s treatment plan. Patients have the explicit option to decline information about potential cancer-promoting genetic changes. Patient follow-up is conducted at regular intervals using standardized questionnaires sent to the treating physicians.

Children and adolescents under the age of 22 who have a tumor that has recurred or progressed following initial treatment are eligible to participate in the study. A prerequisite for participation is the availability of sufficient tumor tissue and a blood sample for genetic analysis. In addition, written consent from the patient or a legal representative must be provided. Patients who have been diagnosed with cancer for the first time and have not yet undergone prior treatment or experienced a relapse are excluded.